Millipore Sigma Vibrant Logo

AB9688 Anti-Tau phospho Threonine 212 Antibody

Detect Tau phospho Threonine 212 using this Anti-Tau phospho Threonine 212 Antibody validated for use in WB.

Anti-Tau phospho Threonine 212 Antibody: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。
Research Category: Neuroscience Research Sub-Category: Neurodegenerative Diseases, Neurofilament & Neuron Metabolism Gene Symbol: MAPT, MTBT2, MAPTL, PHF-tau, tau, DDPAC, FTDP-17, MGC138549, MSTD, TAU, FLJ31424, MTBT1, PPND UniProt Number: P10636
View This Product on Sigma-Aldrich
AB9688
100 µL  
価格を検索中…
価格が見つかりません
Minimum Quantity needs to be mulitiple of
Maximum Quantity is
弊社照会 詳細を表示　
値引
()
 
—
弊社照会
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      Special Offers［海外情報］

       

      お問合せください

      概要

      Replacement Information

      Special Offers［海外情報］

      100% Performance Guaranteed

      主要スペック表

      Species ReactivityKey ApplicationsHostFormatAntibody Type
      HWBRbAffinity PurifiedPolyclonal Antibody
      Description
      Catalogue NumberAB9688
      Brand Family Chemicon®
      Trade Name
      • Chemicon
      DescriptionAnti-Tau phospho Threonine 212 Antibody
      References
      Product Information
      FormatAffinity Purified
      Quality LevelMQ100
      Applications
      ApplicationDetect Tau phospho Threonine 212 using this Anti-Tau phospho Threonine 212 Antibody validated for use in WB.
      Key Applications
      • Western Blotting
      Biological Information
      HostRabbit
      Species Reactivity
      • Human
      Antibody TypePolyclonal Antibody
      Entrez Gene Number
      Entrez Gene SummaryThis gene encodes the microtubule-associated protein tau (MAPT) whose transcript undergoes complex, regulated alternative splicing, giving rise to several mRNA species. MAPT transcripts are differentially expressed in the nervous system, depending on stage of neuronal maturation and neuron type. MAPT gene mutations have been associated with several neurodegenerative disorders such as Alzheimer's disease, Pick's disease, frontotemporal dementia, cortico-basal degeneration and progressive supranuclear palsy.
      Gene Symbol
      • MAPT
      • MTBT2
      • MAPTL
      • PHF-tau
      • tau
      • DDPAC
      • FTDP-17
      • MGC138549
      • MSTD
      • TAU
      • FLJ31424
      • MTBT1
      • PPND
      Modifications
      • Phosphorylation
      UniProt Number
      UniProt SummaryFUNCTION: SwissProt: P10636 # Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity. The C-terminus binds axonal microtubules while the N- terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both. Axonal polarity is predetermined by tau localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization.
      SIZE: 758 amino acids; 78878 Da
      SUBUNIT: Interacts with PSMC2 through SQSTM1 (By similarity). Interacts with SQSTM1 when polyubiquitinated.
      SUBCELLULAR LOCATION: Cytoplasm, cytosol. Cell membrane. Note=Mostly found in the axons of neurons, in the cytosol and in association with plasma membrane components.
      TISSUE SPECIFICITY: Expressed in neurons. Isoform PNS-tau is expressed in the peripheral nervous system while the others are expressed in the central nervous system.DEVELOPMENTAL STAGE: Four-repeat (type II) tau is expressed in an adult-specific manner and is not found in fetal brain, whereas three-repeat (type I) tau is found in both adult and fetal brain.
      DOMAIN: SwissProt: P10636 The tau/MAP repeat binds to tubulin. Type I isoforms contain 3 repeats while type II isoforms contain 4 repeats.
      PTM: Phosphorylation at serine and threonine residues in S-P or T- P motifs by proline-directed protein kinases (PDPK: CDC2, CDK5, GSK-3, MAPK) (only 2-3 sites per protein in interphase, seven-fold increase in mitosis, and in PHF-tau), and at serine residues in K- X-G-S motifs by MAP/microtubule affinity-regulating kinase (MARK) in Alzheimer diseased brains. Phosphorylation decreases with age. Phosphorylation within tau's repeat domain or in flanking regions seems to reduce tau's interaction with, respectively, microtubules or plasma membrane components. Phosphorylation on Ser-610, Ser- 622, Ser-641 and Ser-673 in several isoforms during mitosis. & Polyubiquitinated. Requires functional TRAF6 and may provoke SQSTM1-dependent degradation by the proteasome (By similarity). PHF-tau can be modified by three different forms of polyubiquitination. 'Lys-48'-linked polyubiquitination is the major form, 'Lys-6'-linked and 'Lys-11'-linked polyubiquitination also occur. & Glycation of PHF-tau, but not normal brain tau. Glycation is a non-enzymatic post-translational modification that involves a covalent linkage between a sugar and an amino group of a protein molecule forming ketoamine. Subsequent oxidation, fragmentation and/or cross-linking of ketoamine leads to the production of advanced glycation endproducts (AGES). Glycation may play a role in stabilizing PHF aggregation leading to tangle formation in AD.
      DISEASE: SwissProt: P10636 # In Alzheimer disease, the neuronal cytoskeleton in the brain is progressively disrupted and replaced by tangles of paired helical filaments (PHF) and straight filaments, mainly composed of hyperphosphorylated forms of TAU (PHF-TAU or AD P-TAU). & Defects in MAPT are a cause of frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP17) [MIM:600274, 172700]; also called frontotemporal dementia (FTD) or historically termed Pick complex. This form of frontotemporal dementia is characterized by presenile dementia with behavioral changes, deterioration of cognitive capacities and loss of memory. In some cases, parkinsonian symptoms are prominent. Neuropathological changes include frontotemporal atrophy often associated with atrophy of the basal ganglia, substantia nigra, amygdala. In most cases, protein tau deposits are found in glial cells and/or neurons. & Defects in MAPT are a cause of pallido-ponto-nigral degeneration (PPND) [MIM:168610]. The clinical features include ocular motility abnormalities, dystonia and urinary incontinence, besides progressive parkinsonism and dementia. & Defects in MAPT are a cause of corticobasal degeneration (CBD). It is marked by extrapyramidal signs and apraxia and can be associated with memory loss. Neuropathologic features may overlap Alzheimer disease, progressive supranuclear palsy, and Parkinson disease. & Defects in MAPT are a cause of progressive supranuclear palsy (PSP) [MIM:601104, 260540]; also known as Steele-Richardson- Olszewski syndrome. PSP is characterized by akinetic-rigid syndrome, supranuclear gaze palsy, pyramidal tract dysfunction, pseudobulbar signs and cognitive capacities deterioration. Neurofibrillary tangles and gliosis but no amyloid plaques are found in diseased brains. Most cases appear to be sporadic, with a significant association with a common haplotype including the MAPT gene and the flanking regions. Familial cases show an autosomal dominant pattern of transmission with incomplete penetrance; genetic analysis of a few cases showed the occurrence of tau mutations, including a deletion of Asn-613. & Defects in MAPT may be a cause of hereditary dysphasic disinhibition dementia (HDDD) [MIM:607485]. HDDD is a frontotemporal dementia characterized by progressive cognitive deficits with memory loss and personality changes, severe dysphasic disturbances leading to mutism, and hyperphagia.
      SIMILARITY: Contains 4 Tau/MAP repeats.
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Usage Statement
      • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
      Storage and Shipping Information
      Packaging Information
      Material Size100 µL
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      AB9688 04053252326639

      Documentation

      Anti-Tau phospho Threonine 212 Antibody (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      Anti-Tau phospho Threonine 212 Antibody 試験成績書（CoA）

      タイトルロット番号
      RABBIT ANTI-Tau phosphoThreonine 212 POLYCLONAL ANTIBODY - 2441466 2441466
      RABBIT ANTI-Tau phosphoThreonine 212 - 3164804 3164804
      RABBIT ANTI-Tau phosphoThreonine 212 - 3170774 3170774
      RABBIT ANTI-Tau phosphoThreonine 212 - 3229324 3229324
      RABBIT ANTI-Tau phosphoThreonine 212 - 3920875 3920875
      RABBIT ANTI-Tau phosphoThreonine 212 -2710215 2710215

      Newsletters / Publications

      Title
      Research Focus - Volume 2, 2013

      関連製品＆アプリケーション

      製品ファミリー

      神経系マーカー

      神経系は、個々の随意/不随意運動を調整し、体の異なる部分間での信号を送ります。
      詳細はこちら >>

      Tau Antibodies, Kits & Proteins

      Millipore’s Tau antibodies demonstrates specificity against microtubule binding protein Tau. See below for related products for Tau, based on the expertise of Upstate & Chemicon.
      詳細はこちら >>

      カテゴリー

      Life Science Research > Antibodies and Assays > Primary Antibodies